Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trainline shares 'unfairly discounted', says Shore Capital

(Sharecast News) - Shore Capital has reiterated a 'buy' rating for ticketing platform Trainline, saying the stock is being "unfairly discounted" by the market at current levels. Trainline shares jumped on Thursday after the company provided a first-half update that showed trading was tracking ahead of full-year expectations.

While full-year guidance was unchanged - net ticket sales are expected to grow 6-9% and revenues by 0-3% - Trainline said that adjusted EBITDA growth should come in at the top end of the 6-9% guidance range due to operating leverage and work on costs.

The result, Shore Capital said, is a 2% upgraded to its adjusted EBITDA forecast from £170.8m to £173m.

Looking ahead, the broker said: "We believe TRN's equity is being unfairly discounted due to wider UK government noise. This leaves the Group trading on a 7x EV/EBITDA multiple (14x PER), despite improving margins and a low double-digit FCFY.

"TRN is well positioned, in our view, to take advantage of the growing digitalisation of the UK rail network, explore European TAM opportunities in line with planned increased carrier competition, whilst also leveraging the proprietary technology platform for further customer engagement and B2B potential."

Trainline shares were up 7.4% at 279.2p by 1202 BST.

Share this article

Related Sharecast Articles

ConocoPhillips to buy 42% stake in BP Iraq oil fields
(Sharecast News) - BP said on Friday that it has agreed terms for ConocoPhillips to buy a 42% interest in BP Energy Company of Kirkuk (BP ECKL).
GSK shares fall as cough drug development axed
(Sharecast News) - Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic cough drug after unsuccessful results late-stage clinical trial.
Deutsche Bank downgrades Rotork after ABB takeover
(Sharecast News) - Deutsche Bank downgraded Rotork on Friday to 'hold' from 'buy' and lifted the price target to 503p from 400p after it agreed to be bought by Swiss engineering firm ABB in a £4.1bn deal.
Wise Q1 revenues rise as customer numbers grow
(Sharecast News) - Wise reported an increase in first-quarter revenue on Friday as customer numbers at the money transfer firm rose.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.